{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:11:41Z","timestamp":1792005101937,"version":"4.4.0"},"reference-count":101,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma is a clonal plasma cell malignancy that accounts for slightly more than 10% of all hematologic cancers. In this paper, we present a historically focused review of the disease, from the description of the first case in 1844 to the present. The evolution of drug therapy and stem-cell transplantation for the treatment of myeloma, as well as the development of new agents, is discussed. We also provide an update on current concepts of diagnosis and therapy, with an emphasis on how treatments have emerged from a historical perspective after certain important discoveries and the results of experimental studies.<\/jats:p>","DOI":"10.1182\/blood-2007-10-078022","type":"journal-article","created":{"date-parts":[[2008,3,11]],"date-time":"2008-03-11T08:24:36Z","timestamp":1205223876000},"page":"2962-2972","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":824,"title":["Multiple myeloma"],"prefix":"10.1182","volume":"111","author":[{"given":"Robert A.","family":"Kyle","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111715580857000_B1","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma.","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"2019111715580857000_B2","first-page":"1426","article-title":"Plasma cell disorders.","volume-title":"Cecil Textbook of Medicine","author":"Rajkumar","year":"2007","edition":"23rd ed."},{"key":"2019111715580857000_B3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis of monoclonal gammopathy of undetermined significance.","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"2019111715580857000_B4","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance.","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"2019111715580857000_B5","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111715580857000_B6","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1002\/cncr.20652","article-title":"Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades.","volume":"101","author":"Kyle","year":"2004","journal-title":"Cancer"},{"key":"2019111715580857000_B7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/095952874402700129","article-title":"Remarks on the pathology of mollities ossium with cases.","volume":"27","author":"Solly","year":"1844","journal-title":"Med Chir Trans Lond"},{"key":"2019111715580857000_B8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/095952875003300113","article-title":"Case of mollities and fragilitas ossium, accompanied with urine strongly charged with animal matter.","volume":"33","author":"Macintyre","year":"1850","journal-title":"Med Chir Trans Lond"},{"key":"2019111715580857000_B9","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2000.02318.x","article-title":"Multiple myeloma: an odyssey of discovery.","volume":"111","author":"Kyle","year":"2000","journal-title":"Br J Haematol"},{"key":"2019111715580857000_B10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0140-6736(02)86528-X","article-title":"Chemical pathology.","volume":"2","author":"Bence Jones","year":"1847","journal-title":"Lancet"},{"key":"2019111715580857000_B11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1098\/rstl.1848.0003","article-title":"On the new substance occurring in the urine of a patient with mollities ossium.","volume":"138","author":"Bence Jones","year":"1848","journal-title":"Philos Trans R Soc Lond"},{"key":"2019111715580857000_B12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/BF02933794","article-title":"Ueber bindegewebszellen.","volume":"11","author":"Waldeyer","year":"1875","journal-title":"Arch Microbiol Anat"},{"key":"2019111715580857000_B13","first-page":"137","article-title":"A case of multiple myeloma.","volume":"15","author":"Wright","year":"1900","journal-title":"Trans Assoc Am Phys"},{"key":"2019111715580857000_B14","first-page":"233","article-title":"Die intravitale Untersuchungsmethodik des Knochenmarks.","volume":"38","author":"Arinkin","year":"1929","journal-title":"Folia Haematol"},{"key":"2019111715580857000_B15","first-page":"1001","article-title":"Value of the sternal puncture in the diagnosis of multiple myeloma.","volume":"4","author":"Rosenthal","year":"1938","journal-title":"J Mt Sinai Hosp"},{"key":"2019111715580857000_B16","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/archsurg.1928.01140040002001","article-title":"Multiple myeloma.","volume":"16","author":"Geschickter","year":"1928","journal-title":"Arch Surg"},{"key":"2019111715580857000_B17","volume-title":"Die mikroscopisch-chemisch-pathologische untersuchung","author":"Heller","year":"1846"},{"key":"2019111715580857000_B18","first-page":"842","article-title":"Ueber das Vorkommen des sogenannten Bence Jones' schen Eiweisskorpers im normalen Knochenmark.","volume":"80","author":"Fleischer","year":"1880","journal-title":"Arch Pathol Anatom Physiol Klin Med"},{"key":"2019111715580857000_B19","first-page":"119","article-title":"Immunological reactions of Bence-Jones proteins: II. Differences between Bence-Jones proteins from various sources.","volume":"33","author":"Bayne-Jones","year":"1922","journal-title":"Bull Johns Hopkins Hosp"},{"key":"2019111715580857000_B20","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/1097-0142(195603\/04)9:2<262::AID-CNCR2820090210>3.0.CO;2-B","article-title":"Multiple-myeloma proteins\u201c III. The antigenic relationship of Bence Jones proteins to normal gamma-globulin and multiple-myeloma serum proteins.","volume":"9","author":"Korngold","year":"1956","journal-title":"Cancer"},{"key":"2019111715580857000_B21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1084\/jem.116.2.207","article-title":"The nature of Bence-Jones proteins: chemical similarities to polypeptide chains of myeloma globulins and normal gamma-globulins.","volume":"116","author":"Edelman","year":"1962","journal-title":"J Exp Med"},{"key":"2019111715580857000_B22","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jama.1928.02690370023011","article-title":"Hyperproteinemia associated with multiple myelomas: report of an unusual case.","volume":"90","author":"Perlzweig","year":"1928","journal-title":"JAMA"},{"key":"2019111715580857000_B23","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1039\/tf9373300524","article-title":"A new apparatus for electrophoretic analysis of colloidal mixtures.","volume":"33","author":"Tiselius","year":"1937","journal-title":"Trans Faraday Soc"},{"key":"2019111715580857000_B24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1084\/jem.69.1.119","article-title":"Electrophoretic study of immune sera and purified antibody preparation.","volume":"69","author":"Tiselius","year":"1939","journal-title":"J Exp Med"},{"key":"2019111715580857000_B25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1084\/jem.70.4.399","article-title":"Electrophoretic patterns of normal and pathological human blood, serum, and plasma.","volume":"70","author":"Longsworth","year":"1939","journal-title":"J Exp Med"},{"key":"2019111715580857000_B26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1085\/jgp.35.1.89","article-title":"Electrophoresis of proteins on filter paper.","volume":"35","author":"Kunkel","year":"1951","journal-title":"J Gen Physiol"},{"key":"2019111715580857000_B27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0006-3002(53)90233-9","article-title":"Methode permettant l'etude conjuguee des proprietes electrophoretiques et immunochimiques d'un melange de proteines; application au serum sanguin.","volume":"10","author":"Grabar","year":"1953","journal-title":"Biochim Biophys Acta"},{"key":"2019111715580857000_B28","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4049\/jimmunol.92.3.431","article-title":"Direct immunoelectrophoresis.","volume":"92","author":"Wilson","year":"1964","journal-title":"J Immunol"},{"key":"2019111715580857000_B29","first-page":"211","article-title":"Studies on conditions associated with disturbed gamma globulin formation (gammopathies).","volume":"56","author":"Waldenstr\u00f6m","year":"1961","journal-title":"Harvey Lect"},{"key":"2019111715580857000_B30","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance: natural history in 241 cases.","volume":"64","author":"Kyle","year":"1978","journal-title":"Am J Med"},{"key":"2019111715580857000_B31","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0140-6736(47)90375-9","article-title":"Urethane and stilbamidine in multiple myeloma: report on two cases.","volume":"2","author":"Alwall","year":"1947","journal-title":"Lancet"},{"key":"2019111715580857000_B32","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood.V27.3.328.328","article-title":"A controlled trial of urethane treatment in multiple myeloma.","volume":"27","author":"Holland","year":"1966","journal-title":"Blood"},{"key":"2019111715580857000_B33","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1749-6632.1958.tb42675.x","article-title":"Clinical experiences with sarcolysin in neoplastic diseases.","volume":"68","author":"Blokhin","year":"1958","journal-title":"Ann N Y Acad Sci"},{"key":"2019111715580857000_B34","first-page":"87","article-title":"Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma: IV. L-Phenylalanine mustard (NSC-8806).","volume":"21","author":"Bergsagel","year":"1962","journal-title":"Cancer Chemother Rep"},{"key":"2019111715580857000_B35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood.V30.1.74.74","article-title":"Melphalan in multiple myeloma.","volume":"30","author":"Hoogstraten","year":"1967","journal-title":"Blood"},{"key":"2019111715580857000_B36","first-page":"257","article-title":"A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma.","volume":"16","author":"Maas","year":"1962","journal-title":"Cancer Chemother Rep"},{"key":"2019111715580857000_B37","first-page":"179","article-title":"Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma.","volume":"51","author":"Salmon","year":"1967","journal-title":"Cancer Chemother Rep"},{"key":"2019111715580857000_B38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/mpo.2950130502","article-title":"Response rate and survival in myeloma patients receiving prednisone alone.","volume":"13","author":"McIntyre","year":"1985","journal-title":"Med Pediatr Oncol"},{"key":"2019111715580857000_B39","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","article-title":"Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens.","volume":"208","author":"Alexanian","year":"1969","journal-title":"JAMA"},{"key":"2019111715580857000_B40","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/1097-0142(197402)33:2<533::AID-CNCR2820330231>3.0.CO;2-Z","article-title":"Proceedings: combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU.","volume":"33","author":"Lee","year":"1974","journal-title":"Cancer"},{"key":"2019111715580857000_B41","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/0002-9343(77)90543-5","article-title":"Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.","volume":"63","author":"Case","year":"1977","journal-title":"Am J Med"},{"key":"2019111715580857000_B42","first-page":"3832","article-title":"Combination chemotherapy vs melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials.","volume":"16","author":"Myeloma Trialists' Collaborative Group","year":"1998","journal-title":"J Clin Oncol"},{"key":"2019111715580857000_B43","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM195709122571102","article-title":"Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy.","volume":"257","author":"Thomas","year":"1957","journal-title":"N Engl J Med"},{"key":"2019111715580857000_B44","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000206984","article-title":"Identical twin marrow transplantation in multiple myeloma.","volume":"68","author":"Osserman","year":"1982","journal-title":"Acta Haematol"},{"key":"2019111715580857000_B45","first-page":"1269","article-title":"Identical-twin (syngeneic) marrow transplantation for hematologic cancers.","volume":"76","author":"Fefer","year":"1986","journal-title":"J Natl Cancer Inst"},{"key":"2019111715580857000_B46","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood.V69.4.1262.1262","article-title":"Bone marrow transplantation in multiple myeloma: report from the European Cooperative Group for Bone Marrow Transplantation.","volume":"69","author":"Gahrton","year":"1987","journal-title":"Blood"},{"key":"2019111715580857000_B47","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","article-title":"High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.","volume":"2","author":"McElwain","year":"1983","journal-title":"Lancet"},{"key":"2019111715580857000_B48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2141.1987.tb06890.x","article-title":"Multiple myeloma treated with high dose intravenous melphalan.","volume":"66","author":"Selby","year":"1987","journal-title":"Br J Haematol"},{"key":"2019111715580857000_B49","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.V70.3.869.869","article-title":"High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma.","volume":"70","author":"Barlogie","year":"1987","journal-title":"Blood"},{"key":"2019111715580857000_B50","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma [see comments].","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"2019111715580857000_B51","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma.","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111715580857000_B52","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma [see Comment].","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111715580857000_B53","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma.","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"2019111715580857000_B54","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"2019111715580857000_B55","doi-asserted-by":"crossref","first-page":"899","DOI":"10.4065\/79.7.899","article-title":"Thalidomide: tragic past and promising future.","volume":"79","author":"Rajkumar","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"2019111715580857000_B56","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0140-6736(62)92665-X","article-title":"Thalidomide and congenital abnormalities.","volume":"1","author":"Lenz","year":"1962","journal-title":"Lancet"},{"key":"2019111715580857000_B57","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(61)90927-8","article-title":"Thalidomide and congenital abnormalities.","volume":"2","author":"McBride","year":"1961","journal-title":"Lancet"},{"key":"2019111715580857000_B58","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(62)91702-6","article-title":"Thalidomide.","volume":"1","author":"Woodyatt","year":"1962","journal-title":"Lancet"},{"key":"2019111715580857000_B59","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/cpt196563298","article-title":"Clinical experience with thalidomide in patients with cancer.","volume":"6","author":"Grabstad","year":"1965","journal-title":"Clin Pharmacol Ther"},{"key":"2019111715580857000_B60","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/cpt196563292","article-title":"Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer.","volume":"6","author":"Olson","year":"1965","journal-title":"Clin Pharmacol Ther"},{"key":"2019111715580857000_B61","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis.","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111715580857000_B62","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1200\/JCO.2003.07.200","article-title":"Treatment of plasma cell dyscrasias with thalidomide and its derivatives.","volume":"21","author":"Dimopoulos","year":"2003","journal-title":"J Clin Oncol"},{"key":"2019111715580857000_B63","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0092-8674(94)90396-4","article-title":"The ubiquitin-proteasome proteolytic pathway.","volume":"79","author":"Ciechanover","year":"1994","journal-title":"Cell"},{"key":"2019111715580857000_B64","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents.","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"key":"2019111715580857000_B65","first-page":"4342","article-title":"Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor.","volume":"58","author":"Orlowski","year":"1998","journal-title":"Cancer Res"},{"key":"2019111715580857000_B66","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"2019111715580857000_B67","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1471-4159.1980.tb07873.x","article-title":"Cation-sensitive neutral endopeptidase: isolation and specificity of the bovine pituitary enzyme.","volume":"35","author":"Wilk","year":"1980","journal-title":"J Neurochem"},{"key":"2019111715580857000_B68","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1471-4159.1983.tb11815.x","article-title":"Inhibition of rabbit brain prolyl endopeptidase by n-benzyloxycarbonyl-prolyl-prolinal, a transition state aldehyde inhibitor.","volume":"41","author":"Wilk","year":"1983","journal-title":"J Neurochem"},{"key":"2019111715580857000_B69","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"2019111715580857000_B70","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized Phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111715580857000_B71","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"2019111715580857000_B72","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111715580857000_B73","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111715580857000_B74","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"2019111715580857000_B75","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma.","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111715580857000_B76","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","article-title":"Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): Consensus Statement.","volume":"82","author":"Dispenzieri","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"2019111715580857000_B77","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome.","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"2019111715580857000_B78","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111715580857000_B79","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"key":"2019111715580857000_B80","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111715580857000_B81","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single vs double autologous stem-cell transplantation for multiple myeloma [see comment].","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111715580857000_B82","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.","volume":"106","author":"Blade","year":"2005","journal-title":"Blood"},{"key":"2019111715580857000_B83","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly diagnosed myeloma.","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111715580857000_B84","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"2019111715580857000_B85","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide vs melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"2019111715580857000_B86","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajh.2830330203","article-title":"VAD-based regimens as primary treatment for multiple myeloma.","volume":"33","author":"Alexanian","year":"1990","journal-title":"Am J Hematol"},{"key":"2019111715580857000_B87","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111715580857000_B88","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood.V108.11.795.795","article-title":"A randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone vs dexamethasone alone as primary therapy for newly diagnosed multiple myeloma [abstract].","volume":"108","author":"Rajkumar","year":"2006","journal-title":"Blood"},{"key":"2019111715580857000_B89","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.4065\/82.10.1179","article-title":"Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.","volume":"82","author":"Lacy","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"2019111715580857000_B90","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1182\/blood.V108.11.799.799","article-title":"A randomized phase III trial of lenalidomide plus high-dose dexamethasone vs lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract].","volume":"108","author":"Rajkumar","year":"2006","journal-title":"Blood"},{"key":"2019111715580857000_B91","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","article-title":"Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.","volume":"129","author":"Jagannath","year":"2005","journal-title":"Br J Haematol"},{"key":"2019111715580857000_B92","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.","volume":"91","author":"Harousseau","year":"2006","journal-title":"Haematologica"},{"key":"2019111715580857000_B93","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V108.11.56.56","article-title":"VELCADE\/dexamethasone (Vel\/Dex) vs VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): an interim analysis of the IFM 2005-01 Randomized Multicenter Phase III Trial [abstract].","volume":"108","author":"Harousseau","year":"2006","journal-title":"Blood"},{"key":"2019111715580857000_B94","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/jco.2007.25.18_suppl.8001","article-title":"Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01-01 trial [abstract].","volume":"25","author":"Hulin","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111715580857000_B95","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood-2006-04-019778","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1\/2 study.","volume":"108","author":"Mateos","year":"2006","journal-title":"Blood"},{"key":"2019111715580857000_B96","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1200\/JCO.2007.12.3463","article-title":"Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA Italian Multiple Myeloma Network.","volume":"25","author":"Palumbo","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111715580857000_B97","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 Clinical Study.","volume":"25","author":"Cavo","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111715580857000_B98","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","article-title":"Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.","volume":"102","author":"Maloney","year":"2003","journal-title":"Blood"},{"key":"2019111715580857000_B99","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"2019111715580857000_B100","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"2019111715580857000_B101","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/sj.leu.2404516","article-title":"A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.","volume":"21","author":"Stewart","year":"2007","journal-title":"Leukemia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/6\/2962\/1297557\/zh800608002962.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/6\/2962\/1297557\/zh800608002962.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T23:41:52Z","timestamp":1684280512000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/111\/6\/2962\/24148\/Multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,15]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,3,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-10-078022","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,15]]}}}